Stay updated on Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.

Latest updates to the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed older notices (including the government funding lapse alert and Revision: v3.4.1). These are maintenance-related changes and do not affect the study details.SummaryDifference0.4%

- Check21 days agoChange DetectedA government funding notice was added to the page and the revision was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary link added; capitalization of QC-related labels standardized; page revision updated to v3.4.0 from v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4 and no longer shows v3.3.3, reflecting a minor revision update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA centralized Locations section now lists District of Columbia, Florida, New Jersey, and New York as study sites, replacing separate location subsections and removing the HHS Vulnerability Disclosure link.SummaryDifference0.5%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study content or eligibility details were affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.